Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | STS | P08842 | 9/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.57 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleoylestrone SCHEMBL14803698 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL10037069 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| Oleoylestrone SCHEMBL2669491 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| Oleoylestrone SCHEMBL8069581 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| Oleoylestrone SCHEMBL7929852 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL3955146 | 0.98 | KDM4E (0.60) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL14201209 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL11959216 | 0.95 | KDM4E (0.56) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL3322364 | 0.95 | CYP3A4 (0.66) | KDM4EALDH1A1CYP3A4HSD17B1MAPT | |
| SCHEMBL26659900 | 0.95 | CYP3A4 (0.66) | KDM4EALDH1A1CYP3A4HSD17B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3055 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122274-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | SCHOLAR ROCK, INC. | 2025-04-17 | — | — | US | claimed |
| CN-107614695-B | Methods of treating obesity and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with glucagon receptor antagonist antibodies | 瑞美德生物医药科技有限公司 | 2022-01-25 | — | — | CN | claimed |
| US-20200339697-A1 | Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic Antibodies | REMD BIOTHERAPEUTICS INC (US) | 2020-10-29 | — | — | US | claimed |
| US-10752693-B2 | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies | REMD BIOTHERAPEUTICS, INC. (US) | 2020-08-25 | — | — | US | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-10028952-B2 | Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof | SATIOGEN PHARMACEUTICALS, INC (US) | 2018-07-24 | — | — | US | claimed |
| EP-3119757-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180079820-A1 | Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic Antibodies | REMD BIOTHERAPEUTICS INC (US) | 2018-03-22 | — | — | US | claimed |
| EP-3277830-A1 | METHODS FOR TREATING OBESITY AND NONALCOHOLIC FATTY LIVER DISEASE OR NONALCOHOLIC STEATOHEPATITIS USING GLUCAGON RECEPTOR ANTAGONISTIC ANTIBODIES | REMD Biotherapeutics, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20050025714-A1 | Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant | NOVADEL PHARMA, INC. | 2005-02-03 | — | — | US | claimed |
| US-20040138193-A1 | Oestrogen fatty acid monoester as a hypolipidaemic and antidiabetic agent | OLEOYL-ESTRONE DEVELOPMENTS, S.L. (ES) | 2004-07-15 | — | — | US | claimed |
| US-20040122033-A1 | Combination therapy for the treatment of obesity | MERCK & CO., INC. | 2004-06-24 | — | — | US | claimed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1380300-A1 | OESTROGEN AND FATTY ACID MONOESTER AS A HYPOLIPIDAEMIC AND ANTIDIABETIC AGENT | Oleoyl-Estrone Developments, S.L. (ES) | 2004-01-14 | — | — | EP | claimed |
| US-20030095925-A1 | For rapid absorption through the oral mucosa, resulting in fast onset of effect. | NOVADEL PHARMA INC. | 2003-05-22 | — | — | US | claimed |
| EP-0771817-B1 | Oleate monoesters of estrogens for the treatment of obesity and/or overweight | OLEOYL ESTRONE DEVELOPMENTS S (ES) | 2003-03-26 | — | — | EP | claimed |
| US-5798348-A | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 1998-08-25 | — | — | US | claimed |
| EP-0771817-A2 | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 1997-05-07 | — | — | EP | claimed |